Abstract:Use of active forms of vitamin D is advocated in patients with chronic kidney disease (CKD) for treatment of mineral bone disease because of the presumption that native forms of vitamin D would not undergo significant activation to calcitriol, the most active biological form of vitamin D. We present secondary analysis looking at bone turnover in subjects who completed the randomized, double blind, placebo-controlled trial investigating the effect of cholecalciferol supplementation on vascular function in nondiabetic CKD stage G3-G4 and vitamin D ≤20 ng/mL (Clinical Trials Registry of India: CTRI/2013/05/003648). Patients were randomized (1:1) to receive either two directly observed oral doses of 300,000 IU of cholecalciferol or matching placebo at baseline and 8 weeks. Of the 120 subjects enrolled, 58 in the cholecalciferol group and 59 in the placebo group completed the study. At 16 weeks, the serum 25(OH)D and 1,25(OH)2 D levels increased in the cholecalciferol group but not in the placebo group (between-group difference in mean change: 23.40 ng/mL; 95% CI, 19.76 to 27.06; p < 0.001, and 14.98 pg/mL; 95% CI, 4.48 to 27.18; p = 0.007, respectively). Intact parathyroid hormone (iPTH) decreased in the cholecalciferol group (between-group difference in mean change -100.73 pg/mL (95% CI, -150.50 to -50.95; p < 0.001). Serum total and bone-specific alkaline phosphatase (SAP, BAP) and serum C-terminal cross-linked collagen type I telopeptides (CTX-1) were significantly reduced in cholecalciferol group (between group difference for change in mean: -20.25 U/L; 95% CI, -35.14 to -5.38 U/L; p = 0.008 for SAP; -12.54 U/L; 95% CI, -22.09 to -2.98 U/L; p = 0.013 for BAP; and -0.21 ng/mL; 95% CI, -0.38 to -0.05 ng/mL; p = 0.05 for CTX-1). Correlation analysis showed significant correlation of Δ25(OH)D with ΔiPTH (r = -0.409, p < 0.0001), Δ1,25(OH)2 D (r = 0.305, p = 0.001), ΔSAP (r = -0.301, p = 0.002), ΔBAP (r = -0.264, p = 0.004), and ΔCTX-1 (r = -0.210, p = 0.0230). Cholecalciferol supplementation corrects vitamin D deficiency and is effective in lowering serum intact parathyroid hormone and bone turnover markers in early stages of CKD. © 2017 American Society for Bone and Mineral Research.

Controlled Trial of the Effects of 1,25-Dihydroxycholecalciferol in Patients Treated with Regular Dialysis

1,25-Dihydroxycholecalciferol in Dialysed Patients with Clinically Asymptomatic Renal Osteodystrophy A Controlled Study1

Decreased Renal Function in Association with Administration of 1,25-Dihydroxyvitamin D3 to Patients with Stable, Advanced Renal Failure1

Use of 1,25(OH)2-Vitamin D3 in Prevention of Renal Osteodystrophy: Preliminary Observations

An Evaluation of 1a-Hydroxy-and 1,25-Dihydroxyvitamin D3 in the Treatment of Renal Bone Disease

Unique Effects of 24,25-Dihydroxyvitamin D3 in Uremic Patients

Cholecalciferol Supplementation in Chronic Kidney Disease: Restoration of Vitamin D Status and Impact on Parathyroid Hormone

Amygdaloid lesions impair ingestive responses to 2-deoxy-D-glucose but not insulin.

Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis

Ergocalciferol Versus Calcitriol for Controlling Chronic Kidney Disease Mineral Bone Disorder in Stage 3 to 5 CKD: A Randomized Controlled Trial.

Action of 1,25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats

The Efficacy and Safety of High-Dose Cholecalciferol Therapy in Hemodialysis Patients

The Action of 1,25 (OH)2D3 on Turnover Kinetic, Remodelling Surfaces and Structure of Trabecular Bone in Chronic Renal Failure

The Effect of Vitamin D Supplementation on Bone Metabolic Markers in Chronic Kidney Disease

Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.

[Care for and guidance of patients with extensive tumor surgery in the head-neck area].

The effect of 1,25(OH)_2D_3 on bone metabolism in primary glomerulonephritis patients receiving glucocorticoid treatment

A greedy-but-safe dynamic scheduling strategy for an interactive video-on-demand server

The Effect of 1,25 (OH)2D3 on Bone Mineralization: Ultrastructural Studies in Patients with Renal Osteodystrophy

Effect of a high vs. standard dose of vitamin D3 supplementation on bone metabolism and kidney function in children with chronic kidney disease

Vitamin D in Chronic Kidney Disease and Dialysis Patients